[Form 4/A] Inhibikase Therapeutics, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Amended Form 4 highlights — Inhibikase Therapeutics (IKT) director Vincent Aurentz filed a Form 4/A dated 07/02/2025 to correct the exercise price of a previously reported option grant.

• Instrument: Stock option for 134,427 common shares.
• Corrected exercise price: $2.97 per share (previous filing reported an incorrect price).
• Grant date: 02/21/2025  |  Expiration: 02/21/2035.
• Vesting schedule: 50% on the first anniversary and 50% on the second anniversary of the grant date, contingent on continued service.
• Ownership form: Direct; no shares were bought or sold in the open market, so the company’s share count and public float are unchanged.

This filing is administrative in nature, rectifying a clerical error. It does not indicate any change in the director’s net exposure or signal new information about Inhibikase’s operations or financial outlook.

Insights

Equity Analyst

TL;DR: Administrative correction; no cash outflow, dilution, or trading activity—neutral for shareholders.

The Form 4/A merely adjusts the exercise price of an existing option grant to $2.97. Because the options remain unexercised and vest over two years, the filing has no immediate balance-sheet or cash-flow impact. Share count dilution occurs only upon future exercise and at a premium to today’s sub-$3 price level. The correction underscores compliance quality but carries minimal valuation relevance.

Corporate Governance Specialist

TL;DR: Filing corrects prior error, reflects sound disclosure practice; governance impact neutral.

Promptly amending insider filings when errors surface is a governance positive, but the underlying transaction—an at-market option grant—is routine. No Rule 10b5-1 plan is invoked, and no sale or purchase occurred, limiting market-moving significance. The two-year vesting aligns director incentives with long-term performance. Overall impact on governance risk profile is negligible.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aurentz Vincent

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/25/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.97(1)	02/21/2025		A		134,427		(2)	02/21/2035	Common Stock	134,427	$0	134,427	D

Explanation of Responses:

1. The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.

2. The options will vest and become exercisable in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

	/s/ David McIntyre, attorney-in-fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Inhibikase Therapeutics (IKT) disclose in the latest Form 4/A?

The company corrected the exercise price for a 134,427-share stock option granted to Director Vincent Aurentz, setting it at $2.97.

How many options were affected by the correction?

134,427 options were involved; no common shares were bought or sold.

When do the corrected options vest for IKT’s director?

They vest in two equal installments on the first and second anniversaries of 02/21/2025.

Does this Form 4/A change Inhibikase’s share count or cash position?

No. The filing only amends the exercise price; the options remain unexercised, so there is no immediate dilution or cash flow effect.

What is the expiration date of the corrected option grant?

The options expire on 02/21/2035 if not exercised.